DOGWOOD THERAPEUTICS INC宣布,公司预计在2026年年底前向美国食品药品监督管理局(FDA)提交Halneuron药物二期临床试验的总结报告。此次提交内容将全面涵盖该阶段的研究数据与分析结论。
同时,公司还将呈报详细的生产工艺方案以及三期临床试验的整体开发规划。这一系列提交标志着Halneuron项目从中期研究向关键性临床试验阶段推进的重要里程碑。
DOGWOOD THERAPEUTICS INC宣布,公司预计在2026年年底前向美国食品药品监督管理局(FDA)提交Halneuron药物二期临床试验的总结报告。此次提交内容将全面涵盖该阶段的研究数据与分析结论。
同时,公司还将呈报详细的生产工艺方案以及三期临床试验的整体开发规划。这一系列提交标志着Halneuron项目从中期研究向关键性临床试验阶段推进的重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.